Omeros Corporation Reports First Quarter 2019 Financial Results
– Conference Call Today at
1Q 2019 total and OMIDRIA® revenues were
$21.8 millioncompared to $1.6 millionand $22.0 millionin the first and fourth quarters of 2018, respectively. 1Q 2019 revenues reflect the seasonally lower volume of cataract surgery performed in the first quarter and the timing of normal wholesaler purchases shifting from the end of March to the first week of April.
- “Sell-through” – the number of units sold by wholesalers to ASCs and to hospitals – for 1Q 2019 was a record high, increasing 14 percent from the previous high-water mark set in 4Q 2018. Sell-through in the current quarter has continued to grow at a double-digit rate over the same period in the first quarter.
Net loss in 1Q 2019 was
$24.3 million, or $0.50per share, which includes non-cash expenses of $6.0 million, or $0.12per share. Overall decrease in cash, cash equivalents and short-term investments for the quarter was $13.3 million.
March 31, 2019, the company had cash, cash equivalents and short-term investments available for operations of $47.2 million.
Since the previously reported
FDAmeeting held in the first quarter of 2019, which resulted in a streamlined path to submission of a Biologics License Application (BLA) for narsoplimab in HSCT-TMA, the company has had two additional meetings with FDA. The first covered chemistry, manufacturing and controls (CMC), and the company’s CMC commercialization plan remains on track. In the second, a clinical meeting, Omerosreached agreement with FDAon the large majority of the criteria for the primary endpoint. The company expects to complete agreement on the few remaining details in the very near future and is confident that the efficacy and safety data for narsoplimab will support BLA approval in HSCT-TMA.
CMS recently issued a preliminary decision to establish a unique
permanent HCPCS J-code for OMIDRIA. The decision is expected to be
finalized no later than November with the J-code becoming effective on
the first day of the following quarter. A J-code provides a uniform,
simpler and widely accepted process for providers to bill for OMIDRIA
Medicareand commercial insurance plans.
“We are pleased with the company’s performance to date in 2019, having
made substantial strides on all fronts,” said
First Quarter and Recent Developments
Recent developments regarding OMIDRIA include the following:
The Centers for Medicare & Medicaid Services(CMS) issued a preliminary decision to establish a unique permanent Healthcare Common Procedure Coding System (HCPCS) J-code for OMIDRIA. The preliminary decision is included in the publicly available agenda for the agency’s upcoming HCPCS Workgroup meeting on May 15, 2019. The decision is expected to be finalized no later than November 2019, with the code becoming effective on the first day of the following quarter. If finalized, assignment of a J-code for OMIDRIA would provide a uniform and widely accepted process that is expected to simplify billing for the drug across Medicareas well as commercial insurance plans.
May 2019, the results of a “real-world” clinical study were presented at the annual meeting of the American Society of Cataract and Refractive Surgeryand American Society of Ophthalmic Administratorsheld in San Diego. The study compared the incidence of cystoid macular edema (CME), a sight-threatening complication of cataract surgery, in patients undergoing cataract surgery using OMIDRIA with postoperative NSAIDs alone versus those using postoperative corticosteroids, with and without NSAIDs, in the absence of OMIDRIA. The retrospective analysis of cataract surgery performed on 504 eyes (357 patients) showed that use of OMIDRIA reduced the incidence of CME by 3- to 12-fold compared to published data on cataract procedures performed without OMIDRIA. This study, together with the 17 peer-reviewed articles already published on the benefits of OMIDRIA, supports Omeros’ ongoing efforts to secure permanent separate payment for the drug.
Recent developments regarding narsoplimab, Omeros’ lead human
monoclonal antibody targeting mannan-binding lectin-associated serine
protease-2 (MASP-2) in Phase 3 clinical programs for the treatment of
hematopoietic stem cell transplant-associated thrombotic
microangiopathy (HSCT-TMA), Immunoglobulin A (IgA) nephropathy, and
atypical hemolytic uremic syndrome (aHUS), include the following:
Omeroshas had two additional meetings with the U.S. Food and Drug Administration( FDA) – one to cover chemistry, manufacturing and controls-related topics in preparation for commercialization and, most recently, to finalize the criteria for the HSCT-TMA trial’s primary endpoint on which the clinical data will be assessed. The company’s CMC commercialization plan remains on track. In the clinical meeting, Omerosreached agreement with FDAon the large majority of the criteria for the primary endpoint, which will include both laboratory and organ function components. The meeting included a detailed discussion of the primary endpoint and the company believes that it has a good understanding – and is comfortable with – FDA’s position on the final few remaining details. Omerosexpects to complete agreement on these last few details in the very near future. In light of discussions with FDAand the available data on narsoplimab treatment of HSCT-TMA patients, the company is confident that its efficacy and safety data will support approval.
March 2019, Omeroslaunched a disease education initiative at the annual meeting of the European Society for Blood and Marrow Transplantation(EBMT) with a well-attended educational session sponsored by Omerosand entitled “How do I…diagnose HSCT-TMA.” A focus of the session was the relationship between HSCT-TMA and the broader syndrome of disorders caused by endothelial injury, which is important across the company’s development of MASP-2 inhibitors, including narsoplimab. Omerosalso announced the presentation at EBMT of a case report of resolution of gastrointestinal HSCT-TMA following narsoplimab treatment. The case was presented by Rafael Duarte M.D., Ph.D., F.R.C.P., Associate Professor, Head of Hematopoietic Transplantation and Hemato-oncology Section, University HospitalPuerta de Hierro Majadahonda, Madrid and Secretary of the EBMT. Dr. Duarte described an 18-year-old patient with biopsy-proven HSCT-TMA of the gastrointestinal tract causing severe gastrointestinal bleeding requiring transfusions. Upon receiving narsoplimab, her TMA resolved and all transfusions were discontinued. The patient continues to do well after cessation of narsoplimab treatment.
Omeros’ Phase 3 trial evaluating narsoplimab for IgA nephropathy,
referred to as ARTEMIS-IGAN, continues to enroll. Results from the
Phase 2 study of narsoplimab in IgA nephropathy are expected to be
presented at the annual
Congressof the European Renal Association- European Dialysis and Transplant Associationin Budapestin June. In addition, together with its Academic Leadership Committee of international experts on IgA nephropathy, the company is preparing a series of manuscripts directed to narsoplimab and its IgA nephropathy program with the first manuscript planned for submission soon.
Updates regarding Omeros’ other development programs and platforms
include the following:
The development of small-molecule MASP-2 inhibitors continues, and
lead compounds are being optimized for potency, oral
bioavailability and target selectivity.
Omerosexpects to enter the clinic with an orally administered MASP-2 inhibitor next year.
- The company’s MASP-3 inhibitor, OMS906, is expected to enter clinical trials in the first half of 2020.
- In the company’s Phase 1 trial for OMS527, which targets treatment of addiction and compulsive disorders, the company has completed dosing all six cohorts in the single-ascending-dose portion of the trial, and three multiple-ascending-dose cohorts. The trial is expected to be completed during the second or third quarter of this year. The drug has been well tolerated and pharmacokinetic data are consistent with once-daily dosing with or without food. A Phase 2a study targeting nicotine addiction is planned assuming successful completion of Phase 1.
- In Omeros’ proprietary G protein coupled receptor (GPCR) platform, development efforts are focused on several targets, including GPR174. Based on its data, the company believes that GPR174 controls a major pathway in cancer, and modulation of the receptor could provide a seminal advance in immuno-oncologic treatments for a wide range of solid and liquid tumors. Development continues on small molecule compounds targeting GPR174 with the objective of entering the clinic as soon as possible.
- The development of small-molecule MASP-2 inhibitors continues, and lead compounds are being optimized for potency, oral bioavailability and target selectivity.
May 2019, Omeroslaunched a new corporate website at www.omeros.com. Omeroshas approval for and is finalizing an accounts receivable-based line of credit that, if the company chooses to implement it, would provide for borrowing availability of up to $50 milliondepending on the company’s available borrowing base.
For the quarter ended
Sell-through for 1Q 2019 was a record high, increasing 14 percent from the previous high-water mark set in the 4Q 2018. Sell-through in the current quarter has continued to grow at a double-digit rate over the same period in the first quarter.
Total costs and expenses for the three months ended
For the three months ended
Overall decrease in cash, cash equivalents and short-term investments
for 1Q 2019 was
Conference Call Details
Omeros’ management will host a conference call to discuss the financial
results and to provide an update on business activities. The call will
be held today at
To access the live or subsequently archived webcast of the conference call on the internet, go to the company’s website at www.omeros.com and select “Events” under the Investors section of the website. To access the live webcast, please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.
Omeros is a commercial-stage biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and protein
therapeutics for large-market as well as orphan indications targeting
inflammation, complement-mediated diseases, disorders of the central
nervous system and immune-related diseases, including cancers. The
company’s drug product OMIDRIA® (phenylephrine and ketorolac
intraocular solution) 1% / 0.3% is marketed for use during cataract
surgery or intraocular lens (IOL) replacement to maintain pupil size by
preventing intraoperative miosis (pupil constriction) and to reduce
postoperative ocular pain. In the
Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, cognitive impairment and addictive and compulsive disorders. In addition, Omeros has a diverse group of preclinical programs and a proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and corresponding compounds, a number of which are in preclinical development. The company also exclusively possesses a novel antibody-generating platform.
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, which are subject to the “safe
harbor” created by those sections for such statements. All statements
other than statements of historical fact are forward-looking statements,
which are often indicated by terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “goal,” “intend,” “likely,” “look forward
to,” “may,” “objective,” “plan,” “potential,” “predict,” “project,”
“should,” “will,” “would” and similar expressions and variations
thereof. Forward-looking statements are based on management’s beliefs
and assumptions and on information available to management only as of
the date of this press release. Omeros’ actual results could differ
materially from those anticipated in these forward-looking statements
for many reasons, including, without limitation, risks associated with
product commercialization and commercial operations, unproven
preclinical and clinical development activities, regulatory oversight,
intellectual property claims, competitive developments, litigation, and
the risks, uncertainties and other factors described under the heading
“Risk Factors” in the company’s Annual Report on Form 10-K filed with
|UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(In thousands, except share and per share data)|
|Three Months Ended|
|Product sales, net||$||21,779||$||1,588|
|Costs and expenses:|
|Cost of product sales||131||203|
|Research and development||26,255||18,140|
|Selling, general and administrative||14,632||10,934|
|Total costs and expenses||41,018||29,277|
|Loss from operations||(19,239||)||(27,689||)|
|Basic and diluted net loss per share||$||(0.50||)||$||(0.62||)|
Weighted-average shares used to compute basic and diluted
net loss per share
|UNAUDITED CONSOLIDATED BALANCE SHEET DATA|
|March 31,||December 31,|
|Cash, cash equivalents and short-term investments||$||47,222||$||60,498|
|Total current liabilities||44,505||37,356|
|Convertible Senior Notes||151,182||148,981|
|Total shareholders’ deficit||(121,019||)||(100,156||)|
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations